Reply to "Galantamine and QTc Prolongation"
J Clin Psychiatry 2007;68(1):169-170 [letter]
© Copyright 2017 Physicians Postgraduate Press, Inc.
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: We appreciate and read with interest the comments by Drs. Brashear and Spivey. In response to our case report,1 they presented unpublished data from 2 studies performed by Johnson & Johnson Pharmaceutical Research and Development: 1 in subjects with schizophrenia and 1 in subjects with Alzheimer’s disease. Because these studies are unpublished, we are unable to evaluate important study sample details, such as subject age and gender, comorbid diseases, and concomitant medications, and therefore cannot comment on the relevance of their results to the case that we presented.